Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment
The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the sur...
Saved in:
Published in | Circulation research Vol. 132; no. 10; pp. 1320 - 1337 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
Lippincott Williams & Wilkins
12.05.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1–7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1–7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT
1
AT
2
and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females. |
---|---|
AbstractList | The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1–7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1–7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT
1
AT
2
and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females. The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1-7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1-7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT AT and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females. The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1-7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1-7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT1 AT2 and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females.The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1-7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1-7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT1 AT2 and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females. |
Author | Chappell, Mark C. |
AuthorAffiliation | Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC |
AuthorAffiliation_xml | – name: Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC |
Author_xml | – sequence: 1 givenname: Mark C. surname: Chappell fullname: Chappell, Mark C. organization: Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37167353$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUUtv1DAQtlAR3RZ-AihHLllm_Eg2cEBR2tKVKq20C1wtJ5l0DYnT2llK_3292lIeF-bi0cz3GPk7YUdudMTYa4Q5YobvquW6Wp9vystyjlzMBcfFQjxjM1RcplLleMRmAFCkuRBwzE5C-AaAUvDiBTsWOWa5UGLGVmty1qWlu7bjRC5Yl2zuw0RDYlybbOhncma7jjy5hkISt9Xq6_IsxeJ9UiaVt5NtTJ-UIVAIA7npJXvemT7Qq8f3lH25OP9cXaZXq0_LqrxKG8VFlhpljCpI1TmHfME7DtAZAFnXRbxRcmpk26ISLclc1FKRik0BRLJR0nQLcco-HnRvdvVAbROtven1jbeD8fd6NFb_vXF2q6_HHxoBcxSIUeHto4Ifb3cUJj3Y0FDfG0fjLmi-QKFiQRahb_40e3L59Y0RoA6Axo8heOqeIAh6H5f-HZeOcelDXJH34R9eYycz2XF_s-3_y5YH9t3YT-TD9353R15vyfTTVsfwQQDylAMXoJBDuh9l4gEkzqnj |
CitedBy_id | crossref_primary_10_1016_j_semerg_2023_102187 crossref_primary_10_1186_s10020_024_00855_2 crossref_primary_10_1021_acs_analchem_4c05172 crossref_primary_10_1161_CIRCRESAHA_123_322935 crossref_primary_10_1016_j_bbi_2024_03_037 crossref_primary_10_1186_s13054_023_04739_5 crossref_primary_10_1016_j_compbiomed_2024_109631 crossref_primary_10_1016_j_peptides_2024_171201 crossref_primary_10_1152_ajplung_00372_2024 crossref_primary_10_1007_s10528_024_10813_6 crossref_primary_10_1248_bpb_b23_00568 crossref_primary_10_3390_ijms25189960 crossref_primary_10_1016_j_cophys_2023_100704 crossref_primary_10_1021_acsptsci_4c00120 crossref_primary_10_1007_s11357_024_01487_4 crossref_primary_10_1186_s13054_024_05123_7 |
Cites_doi | 10.1001/jama.2022.15454 10.3389/fimmu.2022.1055811 10.1002/rmv.2223 10.3389/fimmu.2018.00794 10.1038/s41598-022-24628-1 10.1183/13993003.03730-2020 10.1124/pharmrev.120.000281 10.1001/jamanetworkopen.2022.7852 10.1152/physrev.00023.2016 10.1161/CIRCULATIONAHA.116.022385 10.1186/s40249-020-00662-x 10.3390/ijms23137209 10.1016/j.eururo.2015.01.027 10.1038/s41591-022-01840-0 10.1016/j.jpeds.2018.09.058 10.3390/ijms231810968 10.1001/jamainternmed.2022.2476 10.1016/j.isci.2021.102254 10.1016/j.cjco.2021.05.007 10.1080/22221751.2021.1969869 10.1002/hsr2.1011 10.1007/s10456-021-09823-4 10.1186/s12916-020-01851-z 10.1161/HYPERTENSIONAHA.113.01648 10.1016/0022-4731(89)90084-8 10.1016/j.jmii.2022.10.003 10.1093/eurjpc/zwaa155 10.1164/rccm.202106-1514OC 10.1016/j.euf.2020.05.009 10.1177/1087057111413919 10.3390/jcm11247314 10.1164/rccm.202108-1904ED 10.1042/CS20171550 10.1371/journal.pone.0198144 10.1183/23120541.00114-2021 10.1530/JOE-20-0260 10.1038/s41586-022-04479-6 10.1016/j.omtm.2022.07.003 10.1152/physiol.00035.2018 10.1002/jmv.27144 10.1097/CCM.0000000000005589 10.1161/HYPERTENSIONAHA.120.16724 10.1016/j.celrep.2020.108485 10.1183/23120541.00848-2020 10.1038/ki.2013.518 10.1161/CIRCRESAHA.116.303587 10.1152/ajprenal.00677.2013 10.7150/ijms.46695 10.1152/ajpheart.00897.2014 10.1161/CIRCRESAHA.120.317015 10.1038/s41598-021-95308-9 10.1152/ajpregu.1997.273.6.R1908 10.3390/ijms23020927 10.3389/fcvm.2022.847809 10.1038/s41588-020-00759-x 10.1128/spectrum.02362-21 10.3389/fimmu.2020.564526 10.1042/BJ20040634 10.1016/j.cell.2020.04.035 10.1161/HYPERTENSIONAHA.121.18295 10.1093/ehjcvp/pvaa138 10.3390/v15010167 10.1152/ajplung.00129.2021 10.1038/s41562-022-01450-3 10.1128/JVI.00964-21 10.1097/00004872-199606000-00017 10.3389/fcvm.2021.710946 10.3390/ijms21217943 10.1001/jama.2023.3546 10.1002/rmv.2395 10.3389/fcvm.2022.869251 10.1089/andro.2022.0006 10.1136/bmjopen-2021-053032 10.1152/ajpheart.00618.2015 10.1111/andr.12836 10.1152/ajplung.00498.2016 10.1016/j.hlc.2020.11.008 10.3390/cells1010275 10.1016/j.eclinm.2021.101152 10.3389/fendo.2013.00201 10.1038/s41577-021-00662-4 10.1002/jmv.27592 10.1161/01.RES.0000223145.74217.e7 10.1177/1074248417691136 10.1016/S0140-6736(20)31964-4 10.1001/jama.2023.4480 10.1016/j.mce.2022.111775 10.1080/08830185.2022.2089666 10.1164/rccm.202012-4461OC 10.1124/pharmrev.120.000236 10.1038/s41371-022-00771-0 10.1016/j.cell.2020.02.052 10.1186/s13054-020-02862-1 10.1161/HYPERTENSIONAHA.119.14071 10.1016/j.cellimm.2015.02.004 10.1016/j.jtauto.2021.100100 10.1161/CIRCRESAHA.113.300752 10.1038/s41598-021-03181-3 10.1152/ajpheart.00217.2020 10.1016/j.ahj.2021.11.016 10.1016/j.jcv.2020.104392 10.1038/s41586-020-2700-3 10.1177/1753944715597623 10.1016/S0140-6736(19)32317-7 10.1016/j.eclinm.2022.101619 10.1161/HYPERTENSIONAHA.108.114058 10.3317/jraas.2006.015 10.3389/fmed.2020.563893 10.1038/s41598-022-13585-4 10.1001/jamanetworkopen.2022.2735 10.3390/diagnostics12051124 10.1016/j.jaut.2021.102683 10.1016/s0895-7061(97)00400-7 10.1007/s11427-020-1643-8 10.1210/en.2008-1664 10.3389/fimmu.2022.981532 10.1126/sciadv.abn3777 10.1111/bph.13044 10.1016/j.eururo.2021.12.013 10.3389/fcvm.2022.809997 10.1093/ajh/hpaa169 10.1161/JAHA.118.011179 10.1001/jamanetworkopen.2021.11398 10.1161/HYPERTENSIONAHA.120.11941 10.1128/mBio.00974-21 10.1016/j.isci.2022.105748 10.1177/0961203320904787 10.1097/MD.0000000000027072 10.1152/ajpregu.00356.2020 10.3389/fimmu.2022.1028613 10.1186/ar3012 10.1164/rccm.201911-2172OC 10.1371/journal.pone.0250774 10.1016/S0140-6736(20)31561-0 10.1126/science.abb2762 10.1038/s41371-020-0335-3 10.3389/fimmu.2021.684142 10.1723/3148.31294 10.3389/fphys.2022.1080837 10.1038/s41577-021-00634-8 10.1113/expphysiol.2007.040352 10.1038/s41591-020-01227-z 10.1038/s41598-021-03731-9 10.22037/uj.v18i.6691 10.1177/17534666221122544 10.1016/j.bcp.2022.115347 10.1183/16000617.0017-2018 10.26355/eurrev_202110_26865 10.3389/fimmu.2021.756262 10.1152/ajpheart.01277.2007 10.1164/rccm.202001-0179LE 10.4172/2576-1471.1000134 10.1186/ar3052 10.1016/j.tcm.2021.09.009 10.1038/s41598-021-95565-8 10.1038/s41574-022-00780-6 10.7554/eLife.73522 10.1172/jci.insight.158362 10.1016/j.phrs.2021.105924 10.1016/j.bcp.2022.115200 10.1016/j.bcp.2022.115370 10.15252/msb.20209610 10.1186/s12916-022-02345-w 10.1136/annrheumdis-2021-222088 10.3389/fimmu.2021.625732 10.1001/jama.2020.24865 10.1038/s41467-022-28905-5 10.1038/s41591-022-01689-3 10.1016/j.jacc.2022.06.008 10.1161/01.HYP.0000085210.66399.A3 10.1152/ajpheart.00755.2020 10.1038/s41586-022-04474-x 10.3389/fendo.2021.694083 10.1016/j.autrev.2021.102754 10.3389/fendo.2022.940675 |
ContentType | Journal Article |
Copyright | Lippincott Williams & Wilkins 2023 American Heart Association, Inc. 2023 |
Copyright_xml | – notice: Lippincott Williams & Wilkins – notice: 2023 American Heart Association, Inc. 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1161/CIRCRESAHA.123.321883 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4571 |
EndPage | 1337 |
ExternalDocumentID | PMC10171311 37167353 10_1161_CIRCRESAHA_123_321883 00003012-202305120-00006 |
Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GroupedDBID | --- -~X .-D .3C .Z2 01R 0R~ 18M 1J1 29B 2WC 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPXF ABQRW ABVCZ ABXVJ ABZAD ABZZY ACDDN ACEWG ACGFO ACGFS ACILI ACLDA ACNWC ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADGGA ADHPY AE3 AE6 AENEX AFBFQ AFDTB AFUWQ AGINI AHMBA AHOMT AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BAWUL BOYCO BQLVK C45 CS3 DIK DIWNM DU5 E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP GNXGY GQDEL GX1 H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O9- OAG OAH OB2 OK1 OL1 OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OWW OWY OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W3M W8F WH7 WOQ WOW X3V X3W YFH YOC ZFV AAYXX CITATION ACIJW CGR CUY CVF ECM EIF NPM 7X8 5PM ADSXY |
ID | FETCH-LOGICAL-c5236-a5aa59e5b720782f200fa004bb914342ec4dd153de473b45e5e4790ee4c54af83 |
ISSN | 0009-7330 1524-4571 |
IngestDate | Thu Aug 21 18:36:46 EDT 2025 Thu Jul 10 17:41:12 EDT 2025 Thu Apr 03 07:07:17 EDT 2025 Tue Jul 01 04:10:55 EDT 2025 Thu Apr 24 23:09:23 EDT 2025 Fri May 16 04:11:44 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | SARS-CoV-2 androgen estrogen peptidyl-dipeptidase A angiotensin-converting enzyme 2 renin-angiotensin system |
Language | English |
License | This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c5236-a5aa59e5b720782f200fa004bb914342ec4dd153de473b45e5e4790ee4c54af83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
ORCID | 0000-0001-5869-6037 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC10171311 |
PMID | 37167353 |
PQID | 2813555506 |
PQPubID | 23479 |
PageCount | 18 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10171311 proquest_miscellaneous_2813555506 pubmed_primary_37167353 crossref_primary_10_1161_CIRCRESAHA_123_321883 crossref_citationtrail_10_1161_CIRCRESAHA_123_321883 wolterskluwer_health_00003012-202305120-00006 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-May-12 2023-05-12 20230512 |
PublicationDateYYYYMMDD | 2023-05-12 |
PublicationDate_xml | – month: 05 year: 2023 text: 2023-May-12 day: 12 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hagerstown, MD |
PublicationTitle | Circulation research |
PublicationTitleAlternate | Circ Res |
PublicationYear | 2023 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | e_1_3_3_96_2 e_1_3_3_50_2 e_1_3_3_77_2 e_1_3_3_117_2 e_1_3_3_159_2 e_1_3_3_16_2 e_1_3_3_39_2 e_1_3_3_132_2 e_1_3_3_155_2 e_1_3_3_12_2 e_1_3_3_58_2 e_1_3_3_35_2 e_1_3_3_92_2 e_1_3_3_113_2 e_1_3_3_136_2 e_1_3_3_151_2 e_1_3_3_174_2 e_1_3_3_54_2 e_1_3_3_31_2 e_1_3_3_73_2 e_1_3_3_61_2 e_1_3_3_88_2 e_1_3_3_150_2 e_1_3_3_5_2 e_1_3_3_128_2 e_1_3_3_105_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_109_2 e_1_3_3_166_2 e_1_3_3_23_2 e_1_3_3_69_2 e_1_3_3_120_2 e_1_3_3_46_2 e_1_3_3_80_2 e_1_3_3_147_2 e_1_3_3_162_2 e_1_3_3_65_2 e_1_3_3_124_2 e_1_3_3_42_2 e_1_3_3_84_2 e_1_3_3_101_2 e_1_3_3_143_2 e_1_3_3_76_2 e_1_3_3_99_2 e_1_3_3_161_2 e_1_3_3_139_2 e_1_3_3_116_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_131_2 e_1_3_3_177_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_57_2 e_1_3_3_91_2 e_1_3_3_158_2 e_1_3_3_135_2 e_1_3_3_173_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_53_2 e_1_3_3_72_2 e_1_3_3_95_2 e_1_3_3_112_2 e_1_3_3_154_2 e_1_3_3_60_2 e_1_3_3_87_2 e_1_3_3_172_2 e_1_3_3_8_2 e_1_3_3_104_2 e_1_3_3_127_2 e_1_3_3_49_2 e_1_3_3_108_2 e_1_3_3_142_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_68_2 e_1_3_3_146_2 e_1_3_3_169_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_64_2 e_1_3_3_83_2 e_1_3_3_100_2 e_1_3_3_123_2 e_1_3_3_165_2 e_1_3_3_75_2 e_1_3_3_71_2 e_1_3_3_160_2 e_1_3_3_98_2 e_1_3_3_79_2 e_1_3_3_115_2 e_1_3_3_138_2 e_1_3_3_119_2 e_1_3_3_18_2 e_1_3_3_37_2 e_1_3_3_90_2 e_1_3_3_130_2 e_1_3_3_157_2 e_1_3_3_14_2 e_1_3_3_56_2 e_1_3_3_33_2 e_1_3_3_94_2 e_1_3_3_111_2 e_1_3_3_134_2 e_1_3_3_153_2 e_1_3_3_176_2 e_1_3_3_10_2 e_1_3_3_52_2 e_1_3_3_40_2 e_1_3_3_86_2 e_1_3_3_171_2 e_1_3_3_107_2 e_1_3_3_7_2 e_1_3_3_126_2 e_1_3_3_149_2 e_1_3_3_29_2 e_1_3_3_48_2 e_1_3_3_145_2 e_1_3_3_141_2 e_1_3_3_168_2 e_1_3_3_25_2 e_1_3_3_67_2 e_1_3_3_44_2 e_1_3_3_82_2 e_1_3_3_103_2 e_1_3_3_164_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_63_2 e_1_3_3_122_2 e_1_3_3_51_2 e_1_3_3_74_2 e_1_3_3_97_2 e_1_3_3_70_2 e_1_3_3_78_2 e_1_3_3_118_2 e_1_3_3_137_2 e_1_3_3_17_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_59_2 e_1_3_3_110_2 e_1_3_3_156_2 e_1_3_3_32_2 e_1_3_3_55_2 e_1_3_3_93_2 e_1_3_3_114_2 e_1_3_3_152_2 e_1_3_3_133_2 e_1_3_3_175_2 e_1_3_3_62_2 e_1_3_3_85_2 e_1_3_3_170_2 e_1_3_3_89_2 e_1_3_3_6_2 e_1_3_3_106_2 e_1_3_3_129_2 e_1_3_3_28_2 e_1_3_3_148_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_121_2 e_1_3_3_144_2 e_1_3_3_167_2 e_1_3_3_140_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_66_2 e_1_3_3_81_2 e_1_3_3_102_2 e_1_3_3_125_2 e_1_3_3_163_2 |
References_xml | – ident: e_1_3_3_5_2 doi: 10.1001/jama.2022.15454 – ident: e_1_3_3_176_2 doi: 10.3389/fimmu.2022.1055811 – ident: e_1_3_3_6_2 doi: 10.1002/rmv.2223 – ident: e_1_3_3_154_2 doi: 10.3389/fimmu.2018.00794 – ident: e_1_3_3_57_2 doi: 10.1038/s41598-022-24628-1 – ident: e_1_3_3_59_2 doi: 10.1183/13993003.03730-2020 – ident: e_1_3_3_48_2 doi: 10.1124/pharmrev.120.000281 – ident: e_1_3_3_134_2 doi: 10.1001/jamanetworkopen.2022.7852 – ident: e_1_3_3_21_2 doi: 10.1152/physrev.00023.2016 – ident: e_1_3_3_90_2 doi: 10.1161/CIRCULATIONAHA.116.022385 – ident: e_1_3_3_39_2 doi: 10.1186/s40249-020-00662-x – ident: e_1_3_3_167_2 doi: 10.3390/ijms23137209 – ident: e_1_3_3_132_2 doi: 10.1016/j.eururo.2015.01.027 – ident: e_1_3_3_7_2 doi: 10.1038/s41591-022-01840-0 – ident: e_1_3_3_45_2 doi: 10.1016/j.jpeds.2018.09.058 – ident: e_1_3_3_158_2 doi: 10.3390/ijms231810968 – ident: e_1_3_3_3_2 doi: 10.1001/jamainternmed.2022.2476 – ident: e_1_3_3_130_2 doi: 10.1016/j.isci.2021.102254 – ident: e_1_3_3_144_2 doi: 10.1016/j.cjco.2021.05.007 – ident: e_1_3_3_108_2 doi: 10.1080/22221751.2021.1969869 – ident: e_1_3_3_142_2 doi: 10.1002/hsr2.1011 – ident: e_1_3_3_66_2 doi: 10.1007/s10456-021-09823-4 – ident: e_1_3_3_27_2 doi: 10.1186/s12916-020-01851-z – ident: e_1_3_3_91_2 doi: 10.1161/HYPERTENSIONAHA.113.01648 – ident: e_1_3_3_151_2 doi: 10.1016/0022-4731(89)90084-8 – ident: e_1_3_3_10_2 doi: 10.1016/j.jmii.2022.10.003 – ident: e_1_3_3_8_2 doi: 10.1093/eurjpc/zwaa155 – ident: e_1_3_3_67_2 doi: 10.1164/rccm.202106-1514OC – ident: e_1_3_3_149_2 doi: 10.1016/j.euf.2020.05.009 – ident: e_1_3_3_101_2 doi: 10.1177/1087057111413919 – ident: e_1_3_3_166_2 doi: 10.3390/jcm11247314 – ident: e_1_3_3_55_2 doi: 10.1164/rccm.202108-1904ED – ident: e_1_3_3_44_2 doi: 10.1042/CS20171550 – ident: e_1_3_3_121_2 doi: 10.1371/journal.pone.0198144 – ident: e_1_3_3_61_2 doi: 10.1183/23120541.00114-2021 – ident: e_1_3_3_141_2 doi: 10.1530/JOE-20-0260 – ident: e_1_3_3_36_2 doi: 10.1038/s41586-022-04479-6 – ident: e_1_3_3_71_2 doi: 10.1016/j.omtm.2022.07.003 – ident: e_1_3_3_113_2 doi: 10.1152/physiol.00035.2018 – ident: e_1_3_3_58_2 doi: 10.1002/jmv.27144 – ident: e_1_3_3_83_2 doi: 10.1097/CCM.0000000000005589 – ident: e_1_3_3_73_2 doi: 10.1161/HYPERTENSIONAHA.120.16724 – ident: e_1_3_3_156_2 doi: 10.1016/j.celrep.2020.108485 – ident: e_1_3_3_62_2 doi: 10.1183/23120541.00848-2020 – ident: e_1_3_3_117_2 doi: 10.1038/ki.2013.518 – ident: e_1_3_3_22_2 doi: 10.1161/CIRCRESAHA.116.303587 – ident: e_1_3_3_114_2 doi: 10.1152/ajprenal.00677.2013 – ident: e_1_3_3_40_2 doi: 10.7150/ijms.46695 – ident: e_1_3_3_119_2 doi: 10.1152/ajpheart.00897.2014 – ident: e_1_3_3_14_2 doi: 10.1161/CIRCRESAHA.120.317015 – ident: e_1_3_3_77_2 doi: 10.1038/s41598-021-95308-9 – ident: e_1_3_3_112_2 doi: 10.1152/ajpregu.1997.273.6.R1908 – ident: e_1_3_3_94_2 doi: 10.3390/ijms23020927 – ident: e_1_3_3_69_2 doi: 10.3389/fcvm.2022.847809 – ident: e_1_3_3_78_2 doi: 10.1038/s41588-020-00759-x – ident: e_1_3_3_175_2 doi: 10.1128/spectrum.02362-21 – ident: e_1_3_3_97_2 doi: 10.3389/fimmu.2020.564526 – ident: e_1_3_3_49_2 doi: 10.1042/BJ20040634 – ident: e_1_3_3_42_2 doi: 10.1016/j.cell.2020.04.035 – ident: e_1_3_3_26_2 doi: 10.1161/HYPERTENSIONAHA.121.18295 – ident: e_1_3_3_82_2 doi: 10.1093/ehjcvp/pvaa138 – ident: e_1_3_3_35_2 doi: 10.3390/v15010167 – ident: e_1_3_3_54_2 doi: 10.1152/ajplung.00129.2021 – ident: e_1_3_3_2_2 doi: 10.1038/s41562-022-01450-3 – ident: e_1_3_3_174_2 doi: 10.1128/JVI.00964-21 – ident: e_1_3_3_47_2 doi: 10.1097/00004872-199606000-00017 – ident: e_1_3_3_81_2 doi: 10.3389/fcvm.2021.710946 – ident: e_1_3_3_150_2 doi: 10.3390/ijms21217943 – ident: e_1_3_3_126_2 doi: 10.1001/jama.2023.3546 – ident: e_1_3_3_140_2 doi: 10.1002/rmv.2395 – ident: e_1_3_3_147_2 doi: 10.3389/fcvm.2022.869251 – ident: e_1_3_3_31_2 doi: 10.1089/andro.2022.0006 – ident: e_1_3_3_162_2 doi: 10.1136/bmjopen-2021-053032 – ident: e_1_3_3_17_2 doi: 10.1152/ajpheart.00618.2015 – ident: e_1_3_3_28_2 doi: 10.1111/andr.12836 – ident: e_1_3_3_51_2 doi: 10.1152/ajplung.00498.2016 – ident: e_1_3_3_52_2 doi: 10.1016/j.hlc.2020.11.008 – ident: e_1_3_3_63_2 doi: 10.3390/cells1010275 – ident: e_1_3_3_84_2 doi: 10.1016/j.eclinm.2021.101152 – ident: e_1_3_3_18_2 doi: 10.3389/fendo.2013.00201 – ident: e_1_3_3_165_2 doi: 10.1038/s41577-021-00662-4 – ident: e_1_3_3_87_2 doi: 10.1002/jmv.27592 – ident: e_1_3_3_123_2 doi: 10.1161/01.RES.0000223145.74217.e7 – ident: e_1_3_3_146_2 doi: 10.1177/1074248417691136 – ident: e_1_3_3_122_2 doi: 10.1016/S0140-6736(20)31964-4 – ident: e_1_3_3_129_2 doi: 10.1001/jama.2023.4480 – ident: e_1_3_3_164_2 doi: 10.1016/j.mce.2022.111775 – ident: e_1_3_3_177_2 doi: 10.1080/08830185.2022.2089666 – ident: e_1_3_3_56_2 doi: 10.1164/rccm.202012-4461OC – ident: e_1_3_3_75_2 doi: 10.1124/pharmrev.120.000236 – ident: e_1_3_3_115_2 doi: 10.1038/s41371-022-00771-0 – ident: e_1_3_3_15_2 doi: 10.1016/j.cell.2020.02.052 – ident: e_1_3_3_88_2 doi: 10.1186/s13054-020-02862-1 – ident: e_1_3_3_124_2 doi: 10.1161/HYPERTENSIONAHA.119.14071 – ident: e_1_3_3_25_2 doi: 10.1016/j.cellimm.2015.02.004 – ident: e_1_3_3_168_2 doi: 10.1016/j.jtauto.2021.100100 – ident: e_1_3_3_105_2 doi: 10.1161/CIRCRESAHA.113.300752 – ident: e_1_3_3_13_2 doi: 10.1038/s41598-021-03181-3 – ident: e_1_3_3_16_2 doi: 10.1152/ajpheart.00217.2020 – ident: e_1_3_3_143_2 doi: 10.1016/j.ahj.2021.11.016 – ident: e_1_3_3_12_2 doi: 10.1016/j.jcv.2020.104392 – ident: e_1_3_3_137_2 doi: 10.1038/s41586-020-2700-3 – ident: e_1_3_3_20_2 doi: 10.1177/1753944715597623 – ident: e_1_3_3_86_2 – ident: e_1_3_3_23_2 doi: 10.1016/S0140-6736(19)32317-7 – ident: e_1_3_3_170_2 doi: 10.1016/j.eclinm.2022.101619 – ident: e_1_3_3_116_2 doi: 10.1161/HYPERTENSIONAHA.108.114058 – ident: e_1_3_3_120_2 doi: 10.3317/jraas.2006.015 – ident: e_1_3_3_148_2 doi: 10.3389/fmed.2020.563893 – ident: e_1_3_3_161_2 doi: 10.1038/s41598-022-13585-4 – ident: e_1_3_3_80_2 doi: 10.1001/jamanetworkopen.2022.2735 – ident: e_1_3_3_74_2 doi: 10.3390/diagnostics12051124 – ident: e_1_3_3_98_2 doi: 10.1016/j.jaut.2021.102683 – ident: e_1_3_3_46_2 doi: 10.1016/s0895-7061(97)00400-7 – ident: e_1_3_3_70_2 doi: 10.1007/s11427-020-1643-8 – ident: e_1_3_3_111_2 doi: 10.1210/en.2008-1664 – ident: e_1_3_3_99_2 doi: 10.3389/fimmu.2022.981532 – ident: e_1_3_3_103_2 doi: 10.1126/sciadv.abn3777 – ident: e_1_3_3_85_2 doi: 10.1111/bph.13044 – ident: e_1_3_3_133_2 doi: 10.1016/j.eururo.2021.12.013 – ident: e_1_3_3_29_2 doi: 10.3389/fcvm.2022.809997 – ident: e_1_3_3_60_2 doi: 10.1093/ajh/hpaa169 – ident: e_1_3_3_107_2 doi: 10.1161/JAHA.118.011179 – ident: e_1_3_3_153_2 doi: 10.1001/jamanetworkopen.2021.11398 – ident: e_1_3_3_118_2 doi: 10.1161/HYPERTENSIONAHA.120.11941 – ident: e_1_3_3_163_2 doi: 10.1128/mBio.00974-21 – ident: e_1_3_3_65_2 doi: 10.1016/j.isci.2022.105748 – ident: e_1_3_3_96_2 doi: 10.1177/0961203320904787 – ident: e_1_3_3_139_2 doi: 10.1097/MD.0000000000027072 – ident: e_1_3_3_173_2 doi: 10.1152/ajpregu.00356.2020 – ident: e_1_3_3_64_2 doi: 10.3389/fimmu.2022.1028613 – ident: e_1_3_3_100_2 doi: 10.1186/ar3012 – ident: e_1_3_3_89_2 doi: 10.1164/rccm.201911-2172OC – ident: e_1_3_3_160_2 doi: 10.1371/journal.pone.0250774 – ident: e_1_3_3_30_2 doi: 10.1016/S0140-6736(20)31561-0 – ident: e_1_3_3_34_2 doi: 10.1126/science.abb2762 – ident: e_1_3_3_43_2 doi: 10.1038/s41371-020-0335-3 – ident: e_1_3_3_104_2 doi: 10.3389/fimmu.2021.684142 – ident: e_1_3_3_159_2 doi: 10.1723/3148.31294 – ident: e_1_3_3_53_2 doi: 10.3389/fphys.2022.1080837 – ident: e_1_3_3_50_2 doi: 10.1038/s41577-021-00634-8 – ident: e_1_3_3_76_2 doi: 10.1113/expphysiol.2007.040352 – ident: e_1_3_3_33_2 doi: 10.1038/s41591-020-01227-z – ident: e_1_3_3_79_2 doi: 10.1038/s41598-021-03731-9 – ident: e_1_3_3_131_2 doi: 10.22037/uj.v18i.6691 – ident: e_1_3_3_68_2 doi: 10.1177/17534666221122544 – ident: e_1_3_3_145_2 doi: 10.1016/j.bcp.2022.115347 – ident: e_1_3_3_125_2 doi: 10.1183/16000617.0017-2018 – ident: e_1_3_3_135_2 doi: 10.26355/eurrev_202110_26865 – ident: e_1_3_3_157_2 doi: 10.3389/fimmu.2021.756262 – ident: e_1_3_3_109_2 doi: 10.1152/ajpheart.01277.2007 – ident: e_1_3_3_41_2 doi: 10.1164/rccm.202001-0179LE – ident: e_1_3_3_127_2 doi: 10.4172/2576-1471.1000134 – ident: e_1_3_3_93_2 doi: 10.1186/ar3052 – ident: e_1_3_3_9_2 doi: 10.1016/j.tcm.2021.09.009 – ident: e_1_3_3_11_2 doi: 10.1038/s41598-021-95565-8 – ident: e_1_3_3_24_2 doi: 10.1038/s41574-022-00780-6 – ident: e_1_3_3_172_2 doi: 10.7554/eLife.73522 – ident: e_1_3_3_102_2 doi: 10.1172/jci.insight.158362 – ident: e_1_3_3_128_2 doi: 10.1016/j.phrs.2021.105924 – ident: e_1_3_3_155_2 doi: 10.1016/j.bcp.2022.115200 – ident: e_1_3_3_19_2 doi: 10.1016/j.bcp.2022.115370 – ident: e_1_3_3_38_2 doi: 10.15252/msb.20209610 – ident: e_1_3_3_138_2 doi: 10.1186/s12916-022-02345-w – ident: e_1_3_3_106_2 doi: 10.1136/annrheumdis-2021-222088 – ident: e_1_3_3_72_2 doi: 10.3389/fimmu.2021.625732 – ident: e_1_3_3_4_2 doi: 10.1001/jama.2020.24865 – ident: e_1_3_3_92_2 doi: 10.1038/s41467-022-28905-5 – ident: e_1_3_3_169_2 doi: 10.1038/s41591-022-01689-3 – ident: e_1_3_3_171_2 doi: 10.1016/j.jacc.2022.06.008 – ident: e_1_3_3_110_2 doi: 10.1161/01.HYP.0000085210.66399.A3 – ident: e_1_3_3_32_2 doi: 10.1152/ajpheart.00755.2020 – ident: e_1_3_3_37_2 doi: 10.1038/s41586-022-04474-x – ident: e_1_3_3_136_2 doi: 10.3389/fendo.2021.694083 – ident: e_1_3_3_95_2 doi: 10.1016/j.autrev.2021.102754 – ident: e_1_3_3_152_2 doi: 10.3389/fendo.2022.940675 |
SSID | ssj0014329 |
Score | 2.516122 |
SecondaryResourceType | review_article |
Snippet | The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially... |
SourceID | pubmedcentral proquest pubmed crossref wolterskluwer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1320 |
SubjectTerms | Angiotensin-Converting Enzyme 2 - metabolism Angiotensin-Converting Enzyme Inhibitors - pharmacology Compendium on COVID-19 and Cardiovascular Disease COVID-19 Female Humans Male Peptidyl-Dipeptidase A - physiology Post-Acute COVID-19 Syndrome Renin-Angiotensin System - physiology SARS-CoV-2 Sex Characteristics |
Title | Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00003012-202305120-00006 https://www.ncbi.nlm.nih.gov/pubmed/37167353 https://www.proquest.com/docview/2813555506 https://pubmed.ncbi.nlm.nih.gov/PMC10171311 |
Volume | 132 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9NAEF_0BBFEfFtfRPCbbG321azfQryzJ-cVjlb6bckmm7Mo6XHXovjXO_tI0tCCp19C2GSTZX_Z2ZnJzG8QelvRXAtZlpgkfIRhP6Y4YSbHvCwl0VKMqXZsn6diMmefF3zRFcFz2SVrPSx-780r-R9UoQ1wtVmy_4Bs-1BogHPAF46AMByvhfGZqZc1Tuvz5coFoteBgNzHY5pfINCqkM_nwl6z6dfjjziWIR29qXKQtuyc26pqtrwsQm2vd4ESqHUd26yFi_DHwmb7BF9r8B4QF6sXk22BRxhm3JdBGZo9bY2U7NyQmzYU1Qs9m4W9XxoLK42z47MMvqZ0Yh2vdEhBqfC1a_rs16dTdTQ_OVGzw8XsJrpFQO23FSk-LdqQHVDtXNW5dnwhIwte837vS_q6xo4BsRsHe_fnysYoXH13KQpbisbsProXLIQo9XA_QDdM_RDd_hJiIB6h6Q7qkUc9AtQjQD3aQj2Cqw3qH6I0ajCPOswfo_nR4Syb4FAWAxecUIFznudcGq7HxOp3FayIKodVobWEGWLEFKwsYSMrDYOVxrjhcCJHxrCCs7xK6BN0UK9q8wxFosoZq4ysoDcbl0IzSYiMi4QyTUkpBog1E6iKwBlvS5f8UM52FLHq5l3BvCs_7wM0bLtdeNKUv3V406CjQLzZf1Z5bVabK0WSGDRiMKNhLE89Wu0jKdj6Y5AuA5T0cGxvsNTp_Sv18pujULcbkSWaGiDcg1z57GMbkmF9BQTbNQP7FnH0CyPx_BoDfYHudCvtJTpYX27MK9Bc1_q1-5z_AC6AkNw |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renin-Angiotensin+System+and+Sex+Differences+in+COVID-19%3A+A+Critical+Assessment&rft.jtitle=Circulation+research&rft.au=Chappell%2C+Mark+C&rft.date=2023-05-12&rft.issn=1524-4571&rft.eissn=1524-4571&rft.volume=132&rft.issue=10&rft.spage=1320&rft_id=info:doi/10.1161%2FCIRCRESAHA.123.321883&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7330&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7330&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7330&client=summon |